1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Essential Thrombocythemia - Drugs In Development, 2022, provides an overview of the Essential Thrombocythemia (Oncology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Essential thrombocythemia is a chronic myeloproliferative neoplasm in which cells in the bone marrow that produce the blood cells develop and function abnormally. In essential thrombocythemia, there is mainly an overproduction of platelet forming cells (megakaryocytes) in the marrow. Symptoms of essential thrombocythemia include headache, dizziness, weakness or numbness on one side of the body, slurred speech and transient ischemic attacks.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Essential Thrombocythemia - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Essential Thrombocythemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Essential Thrombocythemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Essential Thrombocythemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and IND/CTA Filed stages are 2, 6, 6 and 2 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.
Essential Thrombocythemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Essential Thrombocythemia (Oncology).
- The pipeline guide reviews pipeline therapeutics for Essential Thrombocythemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Essential Thrombocythemia (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Essential Thrombocythemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Essential Thrombocythemia (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Essential Thrombocythemia (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Essential Thrombocythemia (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Essential Thrombocythemia - Overview
- Essential Thrombocythemia - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Essential Thrombocythemia - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Essential Thrombocythemia - Companies Involved in Therapeutics Development
- AbbVie Inc
- F. Hoffmann-La Roche Ltd
- Imago BioSciences Inc
- Innovent Biologics Inc
- IO Biotech Inc
- Italfarmaco SpA
- Johnson & Johnson
- MEI Pharma Inc
- Millennium Pharmaceuticals Inc
- PharmaEssentia Corp
- Shanghai Xunhe Pharmaceutical Technology Co Ltd
- Sino Biopharmaceutical Ltd
- Essential Thrombocythemia - Drug Profiles
- bomedemstat tosylate - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- givinostat - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- IBI-322 - Drug Profile
- Product Description
- Mechanism Of Action
- idasanutlin - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- IO-103 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- IO-112 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- IO-160 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- navitoclax dihydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- peginterferon alfa-2a - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- pevonedistat hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- pracinostat - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ropeginterferon alfa-2b LA - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- TQ-05105 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- VAC-85135 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Vaccine to Target WT1 for Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- veliparib ER - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- XH-5102 - Drug Profile
- Product Description
- Mechanism Of Action
- Essential Thrombocythemia - Dormant Projects
- Essential Thrombocythemia - Discontinued Products
- Essential Thrombocythemia - Product Development Milestones
- Featured News & Press Releases
- Aug 08, 2022: Review of SURPASS-ET trial evaluating Ropeginterferon Alfa-2b-njft for Essential Thrombocythemia (ET) published in Future Oncology
- May 12, 2022: Imago BioSciences announces upcoming presentations on updated data from phase 2 studies of bomedemstat for the treatment of essential thrombocythemia and myelofibrosis at the 27th Congress of the European Hematology Association (EHA) for 2022
- May 03, 2022: Imago BioSciences announces completion of enrollment in phase 2 clinical study of bomedemstat in essential thrombocythemia
- Nov 04, 2021: Imago BioSciences announces oral data presentations at the upcoming 63rd American Society of Hematology Annual Meeting and Exposition
- Oct 21, 2021: PharmaEssentia announces pipeline presentation during upcoming American Society of Hematology Annual Meeting
- Jul 30, 2021: Imago BioSciences receives Orphan Designation from European Medicines Agency for Bomedemstat for the treatment of essential thrombocythemia
- Jun 11, 2021: Imago BioSciences’ bomedemstat demonstrates continued encouraging clinical activity in phase 2 data for treatment of essential thrombocythemia and myelofibrosis at EHA 2021 Virtual Congress
- May 21, 2021: Imago BioSciences to present updated data from phase 2 studies of bomedemstat for the treatment of essential thrombocythemia and myelofibrosis at 2021 European Hematology Association Virtual Congress
- Jan 07, 2021: PharmaEssentia initiates pivotal trial of Ropeginterferon alfa-2b to treat essential thrombocythemia
- Nov 02, 2020: Proof of concept data for Colorista capsules used with Imago BioSciences’ bomedemstat presented at the AAPS Pharmsci 360 Virtual Conference
- Oct 01, 2020: Imago BioSciences doses first patient in phase 2b study of bomedemstat (IMG-7289) in essential thrombocythemia
- Apr 16, 2020: Imago BioSciences appoints Edgardo Baracchini as Chief Business Officer
- Jan 13, 2020: Imago receives fast track designation from U.S. FDA for Bomedemstat for treatment of essential thrombocythemia
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Essential Thrombocythemia, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Essential Thrombocythemia - Pipeline by AbbVie Inc, 2022
- Essential Thrombocythemia - Pipeline by F. Hoffmann-La Roche Ltd, 2022
- Essential Thrombocythemia - Pipeline by Imago BioSciences Inc, 2022
- Essential Thrombocythemia - Pipeline by Innovent Biologics Inc, 2022
- Essential Thrombocythemia - Pipeline by IO Biotech Inc, 2022
- Essential Thrombocythemia - Pipeline by Italfarmaco SpA, 2022
- Essential Thrombocythemia - Pipeline by Johnson & Johnson, 2022
- Essential Thrombocythemia - Pipeline by MEI Pharma Inc, 2022
- Essential Thrombocythemia - Pipeline by Millennium Pharmaceuticals Inc, 2022
- Essential Thrombocythemia - Pipeline by PharmaEssentia Corp, 2022
- Essential Thrombocythemia - Pipeline by Shanghai Xunhe Pharmaceutical Technology Co Ltd, 2022
- Essential Thrombocythemia - Pipeline by Sino Biopharmaceutical Ltd, 2022
- Essential Thrombocythemia - Dormant Projects, 2022
- Essential Thrombocythemia - Discontinued Products, 2022
- Number of Products under Development for Essential Thrombocythemia, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc
- F. Hoffmann-La Roche Ltd
- Imago BioSciences Inc
- Innovent Biologics Inc
- IO Biotech Inc
- Italfarmaco SpA
- Johnson & Johnson
- MEI Pharma Inc
- Millennium Pharmaceuticals Inc
- PharmaEssentia Corp
- Shanghai Xunhe Pharmaceutical Technology Co Ltd
- Sino Biopharmaceutical Ltd
